Literature DB >> 32072593

Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice.

C H Mallinckrodt1, J Bell2, G Liu3, B Ratitch4, M O'Kelly5, I Lipkovich4, P Singh6, L Xu7, G Molenberghs8.   

Abstract

The draft ICH E9(R1) addendum stipulates that an estimator should align with its associated estimand and yield an estimate that facilitates reliable interpretations. The addendum further stipulates that assumptions should be justifiable and plausible, and that the extent of assumptions is an important consideration for whether an estimate will be robust because assumptions are often unverifiable. The draft addendum specifies 5 strategies for dealing with intercurrent events. The intent of this paper is to provide conceptual considerations and technical details for various estimators that align with these strategies. We include focus on how the nature and extent of assumptions influences the potential robustness of the various estimators. The content reflects the knowledge, experience, and opinions of the Drug Information Association's Scientific Working Group on Missing Data. This group includes experienced statisticians from across industry and academia, primarily in the US and European Union.

Entities:  

Keywords:  estimands; estimation; missing data; sensitivity

Mesh:

Year:  2020        PMID: 32072593     DOI: 10.1007/s43441-019-00063-9

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  9 in total

1.  The potential of the estimands framework for clinical pharmacology trials: Some discussion points.

Authors:  Arne Ring; Martin J Wolfsegger
Journal:  Br J Clin Pharmacol       Date:  2020-03-03       Impact factor: 4.335

2.  Treatment estimands in clinical trials of patients hospitalised for COVID-19: ensuring trials ask the right questions.

Authors:  Brennan C Kahan; Tim P Morris; Ian R White; Conor D Tweed; Suzie Cro; Darren Dahly; Tra My Pham; Hanif Esmail; Abdel Babiker; James R Carpenter
Journal:  BMC Med       Date:  2020-09-09       Impact factor: 8.775

3.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration.

Authors:  David M Kent; David van Klaveren; Jessica K Paulus; Ralph D'Agostino; Steve Goodman; Rodney Hayward; John P A Ioannidis; Bray Patrick-Lake; Sally Morton; Michael Pencina; Gowri Raman; Joseph S Ross; Harry P Selker; Ravi Varadhan; Andrew Vickers; John B Wong; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2019-11-12       Impact factor: 25.391

4.  MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC).

Authors:  M Pavic; M Niyazi; L Wilke; S Corradini; M Vornhülz; U Mansmann; A Al Tawil; R Fritsch; J Hörner-Rieber; J Debus; M Guckenberger; C Belka; J Mayerle; G Beyer
Journal:  Radiat Oncol       Date:  2022-01-25       Impact factor: 3.481

5.  Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.

Authors:  C Fletcher; N Hefting; M Wright; J Bell; J Anzures-Cabrera; D Wright; H Lynggaard; A Schueler
Journal:  Ther Innov Regul Sci       Date:  2022-04-24       Impact factor: 1.337

6.  Rethinking intercurrent events in defining estimands for tuberculosis trials.

Authors:  Tra My Pham; Conor D Tweed; James R Carpenter; Brennan C Kahan; Andrew J Nunn; Angela M Crook; Hanif Esmail; Ruth Goodall; Patrick Pj Phillips; Ian R White
Journal:  Clin Trials       Date:  2022-07-19       Impact factor: 2.599

7.  Estimation of treatment effects in short-term depression studies. An evaluation based on the ICH E9(R1) estimands framework.

Authors:  Marian Mitroiu; Steven Teerenstra; Katrien Oude Rengerink; Frank Pétavy; Kit C B Roes
Journal:  Pharm Stat       Date:  2022-06-09       Impact factor: 1.234

8.  Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial.

Authors:  P P J Phillips; A Van Deun; S Ahmed; R L Goodall; S K Meredith; F Conradie; C-Y Chiang; I D Rusen; A J Nunn
Journal:  BMC Med       Date:  2020-11-04       Impact factor: 8.775

9.  The implications of outcome truncation in reproductive medicine RCTs: a simulation platform for trialists and simulation study.

Authors:  Jack Wilkinson; Jonathan Y Huang; Antonia Marsden; Michael O Harhay; Andy Vail; Stephen A Roberts
Journal:  Trials       Date:  2021-08-06       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.